Information Provided By:
Fly News Breaks for December 16, 2019
Dec 16, 2019 | 06:51 EDT
BMO Capital analyst Gary Nachman raised his price target on Horizon Pharma to $40 and kept his Outperform rating after the favorable unanimous FDA vote on teprotumumab. The panelists recognized the drug's "outstanding efficacy for a devastating disease with very high unmet need" and he believes the company's key marketed product Krystexxa and key pipeline product Teprotumumab will be sources of upside going forward, Nachman tells investors in a research note.
News For HZNP From the Last 2 Days
There are no results for your query HZNP